List view / Grid view
Scientists have found that unstable chromosomes within lung tumours increases the risk of cancer returning after surgery, and have used this new knowledge to detect relapse long before standard testing.
Scientists will develop and test promising new molecules for targeting RAS, one of the most common driving mutations in aggressive, hard to treat cancers including pancreatic and lung cancer.
Stem cells are among the most energetically activated, migratory and proliferative sub-populations of tumour cells, according to observations by scholars at the Biomedical Research Centre at the University of Salford.
25 July 2016 | By Niamh Louise Marriott, Digital Content Producer
AbbVie and Bristol-Myers Squibb Company today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie’s investigational biomarker-specific antibody drug conjugate Rova-T...
26 April 2016 | By Victoria White, Drug Target Review
In an exclusive interview, Trevor Perrior, Research Director at Domainex, discusses the cell death regulatory protein FLIP and the potential of FLIP inhibitors as a treatment for NSCLC...
26 April 2016 | By Victoria White, Digital Content Producer
Queen’s University Belfast and Domainex have secured an award to advance therapeutic candidate molecules into clinical evaluation for treatment of NSCLC...
8 April 2016 | By Victoria White, Digital Content Producer
A study found that in addition to decreased overall tumour burden, mice lacking epiregulin also showed reduced inflammation...
23 March 2016 | By Victoria White
Researchers have identified mutations in NSCLC that are key to tumour growth, offering a new way to differentiate patients with the disease...
23 June 2015 | By Victoria White
Blueprint Medicines has announced the first preclinical data for its drug candidate BLU6864, a RET-specific kinase inhibitor.
